NASDAQ:PROF Profound Medical (PROF) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free PROF Stock Alerts $7.90 -0.09 (-1.13%) (As of 01:09 PM ET) Add Compare Share Share Today's Range$7.61▼$7.9050-Day Range$7.70▼$9.2052-Week Range$7.11▼$15.49Volume6,406 shsAverage Volume40,242 shsMarket Capitalization$193.00 millionP/E RatioN/ADividend YieldN/APrice Target$14.58 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Profound Medical alerts: Email Address Profound Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside88.2% Upside$14.58 Price TargetShort InterestHealthy1.28% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.17) to ($1.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.10 out of 5 starsMedical Sector628th out of 907 stocksSurgical & Medical Instruments Industry71st out of 96 stocks 3.5 Analyst's Opinion Consensus RatingProfound Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageProfound Medical has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.28% of the outstanding shares of Profound Medical have been sold short.Short Interest Ratio / Days to CoverProfound Medical has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Profound Medical has recently decreased by 2.94%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProfound Medical does not currently pay a dividend.Dividend GrowthProfound Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PROF. Previous Next 2.4 News and Social Media Coverage News SentimentProfound Medical has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Profound Medical this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Profound Medical to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Profound Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.52% of the stock of Profound Medical is held by insiders.Percentage Held by Institutions47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Profound Medical are expected to grow in the coming year, from ($1.17) to ($1.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Profound Medical is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Profound Medical is -5.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProfound Medical has a P/B Ratio of 6.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Profound Medical Stock (NASDAQ:PROF)Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.Read More PROF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PROF Stock News HeadlinesApril 23, 2024 | msn.comEastern Band of Cherokee Indians Opens North Carolina's First And Only Medical Marijuana Dispensary On 4/20April 22, 2024 | globenewswire.comProfound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to FollowApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 21, 2024 | markets.businessinsider.comIntroducing the Inaugural Dr. Ameer Hassan Scholarship for Medical Students: Pioneering Excellence in Neurology and HealthcareApril 19, 2024 | businesswire.comDr. Cathleen Brown Named Medical Director of Winona, Pioneering Menopause Telehealth CompanyApril 18, 2024 | yahoo.com'Keep him alive': Survivors, Memorial Medical Center salute organ donorsApril 18, 2024 | msn.comMedical Mall Wellness Center Set to Close | April 17, 2024 | News 19 at 6 p.m.April 17, 2024 | finanznachrichten.deAccuryn Medical Announces Leadership TransitionApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 17, 2024 | msn.com'Vibrant Spirit': Hit-And-Run Death Of Ridgefield Teen Leaves 'Profound Void' In 2 CommunitiesApril 15, 2024 | americanbankingnews.comFinancial Survey: Profound Medical (NASDAQ:PROF) vs. Femasys (NASDAQ:FEMY)April 14, 2024 | yahoo.comThe story of love and the challenges faced after a profound medical diagnosisApril 14, 2024 | markets.businessinsider.comIntroducing the Dr. Tyrone Malloy Scholarship for Medical Students: Nurturing Tomorrow's Leaders in Women's HealthApril 14, 2024 | msn.comProfound Autism Summit hosts caregivers in Mass. from across U.S. for 1st timeApril 13, 2024 | seekingalpha.comPRN:CA Profound Medical Corp.April 9, 2024 | yahoo.com'The Good Doctor' Star Bria Henderson Opens Up About a Profound Personal LossApril 9, 2024 | msn.comCook County Clerk Karen Yarbrough dies after being hospitalized with "serious medical condition"April 9, 2024 | globenewswire.comProfound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 6, 2024 | finance.yahoo.comShareholders in Profound Medical (TSE:PRN) are in the red if they invested three years agoApril 3, 2024 | msn.comPersonality has a profound influence on gene expressionApril 3, 2024 | msn.comThe Enduring Legacy of Grey’s Anatomy Celebrating 21 Seasons of Medical Drama ExcellenceApril 2, 2024 | msn.comAsheville Highway Animal Hospital preserves Black medical legacy in East KnoxvilleApril 1, 2024 | mirror.co.ukEXCLUSIVE: 'My baby was brain damaged due to medical negligence - maternity services aren't fit for purpose'April 1, 2024 | msn.comUK teenagers losing ability to socialise offline, warns US’s top medical officerApril 1, 2024 | finance.yahoo.comUltimate Medical Academy Celebrates Commencement for Thousands of Healthcare Student GraduatesApril 1, 2024 | mirror.co.uk'My baby was brain damaged due to medical negligence - maternity services aren't fit for purpose'April 1, 2024 | msn.comTop 10 Medical Miracles of the Century (So Far)See More Headlines Receive PROF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Profound Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/25/2024Next Earnings (Confirmed)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:PROF CUSIPN/A CIK1628808 Webwww.profoundmedical.com Phone(647) 476-1350Fax64-7847-3739Employees131Year FoundedN/APrice Target and Rating Average Stock Price Target$14.58 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+82.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,570,000.00 Net Margins-396.85% Pretax Margin-398.62% Return on Equity-70.18% Return on Assets-53.80% Debt Debt-to-Equity Ratio0.16 Current Ratio6.58 Quick Ratio5.48 Sales & Book Value Annual Sales$7.20 million Price / Sales27.11 Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book6.24Miscellaneous Outstanding Shares24,430,000Free Float24,058,000Market Cap$195.20 million OptionableOptionable Beta0.80 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Arun Swarup Menawat MBA (Age 69)Ph.D., Chairman of the Board & CEO Comp: $551.88kMr. Rashed Dewan (Age 56)Chief Financial Officer Comp: $250.37kDr. Mathieu Burtnyk (Age 42)Chief Operating Officer Comp: $246.1kMr. Hartmut Warnken (Age 51)Chief Commercial Officer of Outside US Comp: $224.93kMr. Abbey Goodman (Age 41)Chief Commercial Officer of US Comp: $353.75kMr. Stephen KilmerInvestor RelationsMr. Jacques F. Cornet (Age 68)Senior VP & Product Leader Sonalleve Mr. Matthew Sobczyk C.A.CPA, Assistant Corporate ControllerMr. Levant TinazSoftware DeveloperMore ExecutivesKey CompetitorsAlpha Tau MedicalNASDAQ:DRTSQuipt Home MedicalNASDAQ:QIPTOrchestra BioMedNASDAQ:OBIOAccurayNASDAQ:ARAYClearPoint NeuroNASDAQ:CLPTView All CompetitorsInstitutional OwnershipRaymond James Financial Services Advisors Inc.Bought 2,913 shares on 4/23/2024Ownership: 2.560%Chilton Investment Co. Inc.Bought 10,000 shares on 2/15/2024Ownership: 0.041%Timelo Investment Management Inc.Sold 61,400 shares on 2/13/2024Ownership: 2.504%Letko Brosseau & Associates Inc.Bought 13,725 shares on 2/12/2024Ownership: 4.821%AIGH Capital Management LLCBought 646,733 shares on 2/12/2024Ownership: 2.647%View All Institutional Transactions PROF Stock Analysis - Frequently Asked Questions Should I buy or sell Profound Medical stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Profound Medical in the last year. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PROF shares. View PROF analyst ratings or view top-rated stocks. What is Profound Medical's stock price target for 2024? 3 Wall Street research analysts have issued 1-year price objectives for Profound Medical's stock. Their PROF share price targets range from $11.00 to $20.00. On average, they expect the company's stock price to reach $14.58 in the next twelve months. This suggests a possible upside of 88.2% from the stock's current price. View analysts price targets for PROF or view top-rated stocks among Wall Street analysts. How have PROF shares performed in 2024? Profound Medical's stock was trading at $8.49 at the beginning of the year. Since then, PROF shares have decreased by 8.7% and is now trading at $7.75. View the best growth stocks for 2024 here. When is Profound Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PROF earnings forecast. How were Profound Medical's earnings last quarter? Profound Medical Corp. (NASDAQ:PROF) released its quarterly earnings data on Thursday, March, 7th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.14. The company earned $2.01 million during the quarter, compared to analyst estimates of $1.90 million. Profound Medical had a negative trailing twelve-month return on equity of 70.18% and a negative net margin of 396.85%. Who are Profound Medical's major shareholders? Profound Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Raymond James Financial Services Advisors Inc. (2.56%). How do I buy shares of Profound Medical? Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PROF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Profound Medical Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
